William Humphries was appointed to the Board on April 12, 2021.  Mr. Humphries joined Alcami Corporation in June 2023 as Chief Executive Officer and a member of its board of directors. He joined Isosceles Pharmaceuticals Inc., a biotechnology company, in May 2021 and serves as its Chief Executive Officer. From August 2018 to December 2020, Mr. Humphries served as President of Ortho Dermatologics, the dermatology division of Bausch Health Companies, Inc., and previously served as its Executive Vice President, Company Group Chairman for Dermatology and OraPharma. Previously, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd. Before joining Merz, he served in a number of leadership positions with Stiefel Laboratories, Inc., including as its Chief Commercial Officer and then as President, where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline. Previously, Mr. Humphries held multiple senior executive roles in sales and marketing, business development and international marketing for Allergan, Inc., concluding as Vice President of its U.S. skincare business. He currently serves as chairman of the board of directors of Clearside Biomedical, Inc., a publicly held biopharmaceutical company, as a director of the publicly held company PhaseBio Pharmaceuticals, Inc., as a director of the privately held company Bryn Pharma and as a director in the privately held company SKNV. He received a Bachelor of Arts from Bucknell University and a Master of Business Administration from Pepperdine University.